We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Custom Antibody Production Services

By Biotechdaily staff writers
Posted on 05 Sep 2002
Custom antibody and recombinant protein production services are being offered by Fusion Antibodies Ltd. (Belfast, Northern Ireland) to pharmaceutical, biotechnology, and academic customers.

The company uses proprietary technology to rapidly produce fusion proteins from genes supplied by clients, using a process based on the company's high-throughput platform that identifies protein fragments from a large number of expression clones. These products can be used as antigens for the production of polyclonal and monoclonal antibodies. The company says it can supply antibodies with 100% efficacy, compared to the current 10-20% efficacy of products manufactured using peptide antigens.

Fusion is developing therapeutic antibodies to treat breast, brain, colorectal, and liver cancer. The company has identified specific surface receptors that are shown to be both unique to these tumors and expressed at later stages in cancer development. In addition, Fusion has a number of targets amenable to monoclonal therapy in various disease states.
The company has established major collaborations with institutes in Europe, Brazil, Singapore, and the US and has clients from academic institutes around the world.




Related Links:
Fusion Antibodies Ltd.

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Thyroid Test
Anti-Thyroid EIA Test
New
Chromogenic Culture System
InTray™ COLOREX™ ECC

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
05 Sep 2002  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
05 Sep 2002  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
05 Sep 2002  |   BioResearch